Compare Regeneron Pharmaceuticals Inc (REGN) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Workiva Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while Workiva Inc trades at $72.69 (market cap $4.01B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 20.8× Workiva Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Workiva Inc pays none. Which is the better fit depends on your goals.
| REGN | WK | |
|---|---|---|
Market Cap | $83.43B | $4.01B |
Sector | Health | Technology |
52-Week High | $852.03 | $93.31 |
52-Week Low | $555.51 | $44.31 |
Enterprise Value | $78.14B | $3.99B |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Workiva (WK) trades at $73.71, down 3.71% today, showing technical support near $72 with bullish moving averages. The company demonstrates strong revenue growth, with 2026 revenue reaching $966 million and net income turning positive at $47 million. Recent earnings beats and high analyst buy ratings (89%) support optimism, though elevated valuation ratios (P/E 87.75) warrant caution.
Outlook remains positive with consistent earnings beats and AI product launches driving growth. Key risks include high valuation multiples and competitive pressures in the SaaS sector. The consensus price target of $82.50 suggests 12% upside potential from current levels, supported by institutional accumulation and strong operational cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
